Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)

M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
被引用次数：119 相关文章 所有 9 个版本

Preclinical studies with erlotinib (Tarceva)

RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
被引用次数：145 相关文章 所有 8 个版本

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature

E Petit-Jean, T Buclin, M Guidi, E Quoix… - Therapeutic drug …, 2015 - journals.lww.com
Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non–
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …
被引用次数：43 相关文章 所有 6 个版本

Erlotinib (Tarceva): an update on the clinical trial program

RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
被引用次数：113 相关文章 所有 7 个版本
[PDF] hal.science

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of …

M Ranson, H Shaw, J Wolf, M Hamilton… - Cancer chemotherapy …, 2010 - Springer
Purpose An intravenous (IV) erlotinib formulation has not been characterized in cancer
patients but may be useful in those with gastrointestinal abnormalities that impact on the …
被引用次数：42 相关文章 所有 19 个版本

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer

JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …
被引用次数：256 相关文章 所有 8 个版本
[HTML] sciencedirect.com

[HTML][HTML] Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer

E Calvo, SN Malik, LL Siu, GM Baillargeon, J Irish… - Annals of oncology, 2007 - Elsevier
Background: The purpose of the study was to evaluate the effects of erlotinib on epidermal
growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients …
被引用次数：42 相关文章 所有 9 个版本

Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

AM Bulgaru, S Mani, S Goel… - Expert review of …, 2003 - Taylor & Francis
Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
被引用次数：62 相关文章 所有 5 个版本

Erlotinib hydrochloride.

JD Minna, J Dowell - Nature Reviews. Drug Discovery, 2005 - europepmc.org
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
被引用次数：50 相关文章 所有 2 个版本
[PDF] narod.ru

Erlotinib hydrochloride.

J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
被引用次数：241 相关文章 所有 14 个版本